Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2023
This is a phase III, randomized, double-blind, placebo-controlled, multi-center, global study to explore the efficacy and safety of volrustomig in women with high-risk LACC (FIGO 2018 stage IIIC to IVA cervical cancer with lymph node involvement) who have not progressed following platinum-based CCRT.
Epistemonikos ID: 9b9d3458267961c43934a95b6075e381c6f6f802
First added on: May 15, 2024